Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
ENDOLOGIX INC (ELGX)
|
Add to portfolio |
|
|
|
| Price: |
$0.10
| | Metrics |
| OS: |
20.7
|
M
| |
-210
|
% ROE
|
| Market cap: |
$2.17
|
M
| |
-208
|
% ROIC
|
|
Net debt:
|
$174
|
M
| |
|
|
|
EV:
|
$176
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($47.5)
|
M
| |
|
|
|
EBIT
|
($53.8)
|
M
| |
|
|
| EPS |
($3.03)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 | Dec-31-13 | Dec-31-12 |
| Revenues | 143.4 | 156.5 | 181.2 | 192.9 | 153.6 | 147.6 | 132.3 | 105.9 |
| Revenue growth | -8.4% | -13.6% | -6.1% | 25.6% | 4.1% | 11.6% | 24.8% | 27.0% |
| Cost of goods sold | 52.3 | 64.6 | 59.8 | 69.1 | 51.8 | 41.8 | 32.8 | 25.2 |
| Gross profit | 91.1 | 91.9 | 121.3 | 123.8 | 101.8 | 105.8 | 99.5 | 80.8 |
| Gross margin | 63.5% | 58.7% | 67.0% | 64.2% | 66.3% | 71.7% | 75.2% | 76.2% |
| Sales and marketing | 64.7 | 76.9 | 92.4 | 107.8 | 78.2 | 73.4 | 63.6 | 54.0 |
| Research and development | 18.1 | 20.8 | 21.0 | 32.3 | 26.4 | 21.6 | 16.2 | 16.6 |
| General and administrative | 36.0 | 43.5 | 35.3 | 41.0 | 29.6 | 26.7 | 21.4 | 20.3 |
| EBITA | -38.1 | -60.7 | -36.2 | -75.5 | -51.6 | -28.5 | -10.1 | -21.2 |
| EBITA margin | -26.6% | -38.8% | -20.0% | -39.2% | -33.6% | -19.3% | -7.6% | -20.0% |
| Amortization of intangibles | 3.6 | 4.2 | 4.1 | 3.8 | 1.3 | 0.6 | 0.3 | 0.7 |
| EBIT | -41.7 | -64.9 | -40.3 | -79.3 | -52.9 | -29.1 | -10.4 | -21.9 |
| EBIT margin | -29.1% | -41.5% | -22.3% | -41.1% | -34.4% | -19.7% | -7.8% | -20.7% |
| Pre-tax income | -69.5 | -79.4 | -66.9 | -154.2 | -59.8 | -32.5 | -16.1 | -35.2 |
| Income taxes | -4.7 | 0.3 | -0.5 | 0.5 | -9.3 | -0.1 | 0.0 | 0.5 |
| Tax rate | 6.8% | | 0.7% | | 15.6% | 0.2% | 0.1% | |
| Net income | -64.8 | -79.7 | -66.4 | -154.7 | -50.4 | -32.4 | -16.1 | -35.8 |
| Net margin | -45.2% | -50.9% | -36.7% | -80.2% | -32.8% | -22.0% | -12.1% | -33.8% |
| |
| Diluted EPS | ($3.84) | ($9.07) | ($7.97) | ($19.10) | ($0.75) | ($0.50) | ($0.26) | ($0.60) |
| Shares outstanding (diluted) | 16.9 | 8.8 | 8.3 | 8.1 | 67.7 | 65.2 | 62.6 | 59.8 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|